Pfizer Inc. PFE announced that the FDA has approved a supplemental new drug application (sNDA) for its eczema drug, Eucrisa (crisaborole) ointment, 2%. The sNDA sought label expansion of Eucrisa for ...

Atopic dermatitis (AD), commonly called eczema, affects approximately 15 percent of children worldwide and one to three percent of adults. Although often a harmless, topical skin disorder that causes ...

Pfizer Inc. PFE announced top-line results from a late-stage study, which evaluated its PDE4 inhibitor, Eucrisa (crisaborole ointment, 2%), for the treatment of mild to moderate atopic dermatitis (AD) ...

EUCRISA™ is a new, steroid-free, topical ointment for mild to moderate atopic dermatitis (eczema) 1 First prescription treatment indicated for mild to moderate AD to be approved in more than 10 years ...

Nearly 18 million children and adults across the United States live with atopic dermatitis (AD), also known as eczema. 1 About 90 percent of those with eczema have the mild-to-moderate form of the ...

With the winter months comes colder, drier air, which can impact those prone to atopic dermatitis (AD), also known as eczema. 1,2 But for the nearly 18 million children and adults in the U.S. living ...